Dr. Cecilia Fu is an Associate Professor of Clinical Pediatrics at the Keck School of Medicine and is a member of the Leukemia and Lymphoma Program within the Children’s Center for Cancer and Blood Diseases at CHLA. Her clinical and research activities have focused on the care of leukemia/ lymphoma patients, with particular research interest in relapsed pediatric leukemias and developmental therapeutics, infant acute lymphoblastic leukemia, chronic myeloid leukemia (CML), acute promyelocytic leukemia (APL), supportive care and late effects of cancer treatment. She is also invested in issues of health disparities and ethnic/racial diversity and efforts to improve the care of children of all children with cancer.
She is an active clinical researcher in the Children’s Oncology Group, serving on the Chronic Myeloid Leukemia, the APL and Diversity and Health Disparities Committees. She is on the study committee of several COG clinical trials. Dr. Fu graduated with honors from the University of Michigan and obtained her medical degree from Wayne State University. She completed her pediatric residency and pediatric hematology oncology fellowship training at Children’s Hospital Los Angeles.
She has been involved for many years as a physician volunteer for Camp Ronald McDonald for Good Times, a camp for children with cancer and their siblings.
Wayne State University School of Medicine
Children's Hospital Los Angeles - Pediatrics Internship
Children's Hospital Los Angeles - Pediatrics Residency
Children's Hospital Los Angeles - Pediatric Hematology/Oncology
Pediatrics - American Board of Pediatrics
Pediatric Hematology/Oncology - American Board of Pediatrics
American Association for Cancer Research
American Society of Clinical Oncology
American Society of Hematology
American Society for Pediatric Hematology/Oncology
Children’s Oncology Group
Clinical and microbiologic outcomes of quinolone prophylaxis in children with acute myeloid leukemia. Felsenstein S, Orgel E, Rushing T, Fu C, Hoffman JA. Pediatr Infect Dis J. 2015 Apr;34(4):e78-84
Obesity is associated with residual leukemia following induction therapy for childhood B-precursor acute lymphoblastic leukemia. Orgel E, Tucci J, Alhushki W, Malvar J, Sposto R, Fu CH, Freyer DR, Abdel-Azim H, Mittelman SD. Blood. 2014 Dec 18;124(26):3932-8
Higher dose imatinib for children with de novo chronic phase chronic myelogenous leukemia: a report from the Children's Oncology Group. Champagne MA, Fu CH, Chang M, Chen H, Gerbing RB, Alonzo TA, Cooley LD, Heerema NA, Oehler V, Wood C, French ME, Arceci RJ, Smith FO, Bernstein ML. Pediatr Blood Cancer. 2011 Jul 15;57(1):56-62
PEG-asparaginase. Fu CH, Sakamoto KM. Expert Opin Pharmacother. 2007 Aug;8(12):1977-84
Reversal of cytosine arabinoside (ara-C) resistance by the synergistic combination of 6-thioguanine plus ara-C plus PEG-asparaginase (TGAP) in human leukemia lines lacking or expressing p53 protein. Fu CH, Martin-Aragon S, Weinberg KI, Ardi VC, Danenberg PV, Avramis VI. Cancer Chemother Pharmacol. 2001 Aug;48(2):123-33
- Infant acute lymphoblastic leukemia
- Chronic myeloid leukemia
- Acute promyelocytic leukemia
- Relapse leukemias
- Supportive care